Bupropion, naltrexone

Sold as Contrave

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

Loading Wikipedia summary

Registration

Applicants: 1
Registrations: 1

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Inova Pharmaceuticals (Pty) LtdCertificate held by Acino Pharma (Pty) Ltd	Contrave	8 mg/90 mg	520478	Not determined	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Contrave Each Prolonged release tablet contains: Bupropion Hydrochloride 90,0 mg and Naltrexone Hydrochloride 8,0 mg	8 mg/90 mgProlonged-release tablet.	52047852/11.3/0478Approved 25 April 2023	Registered	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

S5: Bupropion
Consolidated Schedules 06 July 2026, line 9290
S4: Naltrexone
Consolidated Schedules 06 July 2026, line 7208

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Professional information (PI)For healthcare professionalsContrave, Inova Pharmaceuticals (Pty) Ltd Patient information leaflet (PIL)For patients and carersContrave, Inova Pharmaceuticals (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background